Perfromance Wealth Partners LLC Boosts Position in IDEXX Laboratories, Inc. $IDXX

Perfromance Wealth Partners LLC raised its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 28.2% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,746 shares of the company’s stock after buying an additional 825 shares during the quarter. Perfromance Wealth Partners LLC’s holdings in IDEXX Laboratories were worth $2,009,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of IDXX. MorganRosel Wealth Management LLC bought a new stake in shares of IDEXX Laboratories during the 1st quarter valued at about $26,000. Opal Wealth Advisors LLC bought a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at about $29,000. Migdal Insurance & Financial Holdings Ltd. boosted its position in shares of IDEXX Laboratories by 55.6% during the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company’s stock valued at $35,000 after acquiring an additional 30 shares during the last quarter. Ameritas Advisory Services LLC bought a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at about $36,000. Finally, WPG Advisers LLC bought a new stake in shares of IDEXX Laboratories during the 1st quarter valued at about $37,000. Institutional investors own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on IDXX. JPMorgan Chase & Co. lifted their price target on IDEXX Laboratories from $550.00 to $675.00 and gave the company an “overweight” rating in a research report on Monday, August 4th. Weiss Ratings restated a “buy (b-)” rating on shares of IDEXX Laboratories in a research report on Wednesday, October 8th. Leerink Partners boosted their target price on IDEXX Laboratories from $580.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, July 17th. Jefferies Financial Group began coverage on IDEXX Laboratories in a research report on Tuesday, July 1st. They issued a “buy” rating and a $625.00 target price for the company. Finally, UBS Group began coverage on IDEXX Laboratories in a research report on Wednesday, October 1st. They issued a “neutral” rating and a $720.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $656.50.

Insider Activity

In other news, EVP Michael Lane sold 8,411 shares of the business’s stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $627.74, for a total transaction of $5,279,921.14. Following the transaction, the executive vice president directly owned 7,132 shares of the company’s stock, valued at approximately $4,477,041.68. The trade was a 54.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director M Anne Szostak sold 2,187 shares of the business’s stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $647.33, for a total value of $1,415,710.71. Following the transaction, the director directly owned 262 shares in the company, valued at $169,600.46. This trade represents a 89.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 54,057 shares of company stock valued at $34,293,468. 0.98% of the stock is owned by insiders.

IDEXX Laboratories Price Performance

IDXX opened at $633.32 on Tuesday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $688.12. The stock has a market capitalization of $50.67 billion, a PE ratio of 52.73, a price-to-earnings-growth ratio of 3.99 and a beta of 1.58. The stock’s 50 day moving average price is $640.50 and its 200-day moving average price is $545.08.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.28 by $0.35. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The firm had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.06 billion. During the same period in the previous year, the firm earned $2.44 earnings per share. The business’s revenue was up 10.6% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, equities research analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.